Kevin John Conway - 09 Feb 2026 Form 4 Insider Report for Generation Bio Co. (GBIO)

Reporting relationship: CHIEF FINANCIAL OFFICER
Issuer ticker: GBIO
Reported as of: 09 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Feb 2026, 17:32:08 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Shawna-Gay White, Attorney-in-Fact

Key filing fact

Kevin John Conway filed Form 4 for Generation Bio Co. (GBIO) on 09 Feb 2026.

Key facts

This page summarizes Kevin John Conway's Form 4 filing for Generation Bio Co. (GBIO).
15 reported transactions and 14 derivative rows are listed below.
Accepted by SEC: 09 Feb 2026, 17:32.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002051408 Primary reporting owner

Conway Kevin John

Relationship: CHIEF FINANCIAL OFFICER
Address: C/O GENERATION BIO CO., 301 BINNEY ST, SUITE 401, CAMBRIDGE
Signature: /s/ Shawna-Gay White, Attorney-in-Fact
Signature date: 09 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GBIO transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
Shares: -2,072
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,192
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,192
Exercise price: $63.59
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -283
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 283
Exercise price: $51.58
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,061
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,061
Exercise price: $190.00
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -621
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 621
Exercise price: $302.50
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,399
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,399
Exercise price: $316.90
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -2,585
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,585
Exercise price: $64.90
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -2,800
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,800
Exercise price: $81.80
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -5,940
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,940
Exercise price: $18.60
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -200
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200
Exercise price: $42.90
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -249
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 249
Exercise price: $31.60
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -35,525
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,525
Exercise price: $9.26
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,877
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,877
Exercise price: $47.05
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -550
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 550
Exercise price: $50.60
Footnotes: F3

GBIO transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -1,763
Change %: -100%
Price
Shares after: 0
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,763
Exercise price: $13.90
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Kevin John Conway is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Generation Bio. Co. (the "Issuer"), XOMA Royalty Corporation ("Parent") and Parent's wholly-owned subsidiary, XRA 7 Corp. ("Merger Sub"), dated as of December 15, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Merger Sub prior to the expiration time of the Offer were exchanged for (i) a purchase price of $4.2913 per Share to the stockholders in cash, without interest and less any applicable tax withholding (the "Cash Amount"), plus (ii) one non-tradeable contingent value right per Share (the "CVR"),

Footnote F2

(continued from footnote 1) which represents the right to receive certain contingent payments in cash in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent, with an estimated maximum contingent consideration amount of $25.01 per CVR (the Cash Amount plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Merger Sub merged with and into the Issuer, effective as of February 9, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

Footnote F3

Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was equal to or greater than the Cash Amount was automatically cancelled for no consideration.